Brought to you by 
Lilly joins in on development of AZ's BACE inhibitor; companies to co-promote; second project added
12 Jun 2018
Executive Summary
Eli Lilly & Co. will lead development activities for AstraZeneca PLC’s oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293, which completed Phase I trials for Alzheimer’s disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly joins in on development of AZ's BACE inhibitor; companies to co-promote; second project added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice